Frontiers Oncology., 14 January 2025 .
Introduction :
Patients with extensive-stage small cell lung cancer (ES-SCLC) have a poor Q6 prognosis and there is no standard protocol for NAINTENANCE TREATMENT. ANLOTINIB as a third-line or beyond therapy For ES-SCLC was proved to be Effective .
Methods :
We Retrospectively Screened of Patients with ES-SCLC who started receiving ANLOTINIB as first-line or second-line therapy at the Second Affiliated Hospital of Chongqing Medical University from November 2018 to December 2022 . 30 patients treated with ANLOTINIB based combination therapy and subsequent NAINTENANCE therapy were included .
The primary study endpoint was Progression-Free Survival (PFS) and the secondary study endpoints were OVERALL SURVIVAL (OS), clinical response and adverse events (AEs) .
In 30 ES-SCLC Patients, The Median PFS and OS were 7.2 Months and 17.6 months Respectively .
The ORR and DCR Were 50.0%(15/30) and 86.7% (26/30) respectively .
The Median PFS was 8.2 months and 5.6 months for patients who received synchronized Immunotherapy or Chemotherapy .
The Median OS Was 20.1 Months and 15.1 Months for Patients who received synchronized Immunotherapy or Chemotherapy .
The Median time to intracranial progression (TTP) was 7.2 months for patients who were without brain metastases before receiving ANLOTINIB .
No unexpected AEs were reported. Grade 3-4 adverse events were reported in 10 patients (33.3%). No treatment-related deaths occurred during this study .
Our study has indicated the good efficacy and safety about the application of ANLOTINIB in the NAINTENANCE THERAPY in the first-line or second-line Treatment of ES-SCLC and it can also achieve good intracranial control .